lutetium has been researched along with Carcinoid Tumor in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Bahmad, HF; Burton, LP; Chaaya, G; Elajami, MK; Schwartz, M | 1 |
| Datta, D; Jha, CK; Mishra, A; Patil, S; Pradhan, PK; Yadav, SK | 1 |
| Baio, SM; Bodei, L; Colandrea, M; Fazio, N; Galetta, D; Gilardi, L; Grana, CM; Mariniello, A; Paganelli, G; Papi, S; Tinelli, C; Valmadre, G | 1 |
| Horgan, N; Martin, AI | 1 |
| Bakker, WH; de Herder, WW; Krenning, EP; Kwekkeboom, DJ; van Aken, MO; van Essen, M | 1 |
| Ahlman, H; Bernhardt, P; Forssell-Aronsson, E; Kölby, L; Nilsson, O; Oddstig, J | 1 |
| Ahlman, H; Bernhardt, P; Forssell-Aronsson, E; Johanson, V; Kölby, L; Nilsson, O; Schmitt, A; Stridsberg, M; Swärd, C | 1 |
1 review(s) available for lutetium and Carcinoid Tumor
| Article | Year |
|---|---|
Lutetium therapy-induced carcinoid crisis: A case report and review of literature.
Topics: Bronchial Neoplasms; Carcinoid Tumor; Humans; Lutetium; Male; Middle Aged; Prognosis; Radiopharmaceuticals | 2020 |
6 other study(ies) available for lutetium and Carcinoid Tumor
| Article | Year |
|---|---|
Repurposed Effect of
Topics: Adult; Aged, 80 and over; Carcinoid Tumor; Humans; Lutetium; Lymphoma, Mantle-Cell; Male; Radiopharmaceuticals; Somatostatin | 2022 |
Long-term results of PRRT in advanced bronchopulmonary carcinoid.
Topics: Aged; Carcinoid Tumor; Carcinoma, Neuroendocrine; Cohort Studies; Creatinine; Data Collection; Disease Progression; Disease-Free Survival; Europe; Female; Follow-Up Studies; Humans; Lutetium; Male; Middle Aged; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Octreotide; Odds Ratio; Organometallic Compounds; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Retrospective Studies; Treatment Outcome | 2016 |
Radiolabelled somatostatin analogue treatment in a case of carcinoid tumour with choroidal metastases.
Topics: Biopsy, Fine-Needle; Bronchial Neoplasms; Carcinoid Tumor; Choroid Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Lutetium; Octreotide; Radioisotopes; Somatostatin; Tomography, X-Ray Computed; Young Adult | 2012 |
Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin.
Topics: Adult; Aged; Bronchial Neoplasms; Carcinoid Tumor; Disease Progression; Female; Humans; Lutetium; Male; Medical Oncology; Middle Aged; Octreotide; Peptides; Radioisotopes; Remission Induction; Stomach Neoplasms; Thymus Neoplasms; Treatment Outcome | 2007 |
Effects of treatment with (177)Lu-DOTA-Tyr(3)-octreotate on uptake of subsequent injection in carcinoid-bearing nude mice.
Topics: Animals; Carcinoid Tumor; Cell Line, Tumor; Dose-Response Relationship, Radiation; Humans; Indium Radioisotopes; Injections, Intravenous; Lutetium; Mice; Mice, Nude; Octreotide; Organometallic Compounds; Radioisotopes; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2007 |
Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1.
Topics: Animals; Carcinoid Tumor; Chromogranin A; Humans; Intestinal Neoplasms; Lutetium; Mice; Mice, Nude; Octreotide; Organometallic Compounds; Radiotherapy Dosage; Receptors, Somatostatin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |